Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find ...

Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.

A cancer treatment described as 'the best early Christmas present I could've asked for', has been given FDA and NICE approval.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients with cutaneous ...

HealthDay News — For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and has a favorable risk-benefit ...

A biotech firm based in Milton Park, Oxfordshire, has received a major boost after its T-cell therapy was awarded ...

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

Eye cancer is rare, but in India, the burden is quite high. While over 70% to 80% of cases are detected in adults, the rest ...

Here, the authors develop a multimodal concept-based interpretable model (MMCBM) to distinguish uveal melanoma from hemangioma and metastatic carcinoma, obtaining performance comparable to senior ...

Study findings show that the standardized 6-month surveillance protocols for all patients with low-risk uveal melanoma may be ...

A multi-institutional study led by Moffitt Cancer Center found that percutaneous hepatic perfusion using a melphalan hepatic delivery system may help patients with a rare eye cancer that ...